심혈관 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 연구 설계별, 적응증별, 지역별, 부문별 예측(2023-2030년)

Cardiovascular Clinical Trials Market Growth & Trends:

The global cardiovascular clinical trials market size is expected to reach USD 8.41 billion by 2030, registering a CAGR of 6.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market's growth is majorly due to the increasing prevalence of cardiovascular diseases such as heart failure, stroke, and coronary artery diseases. Furthermore, the persistent advancements in medical research, including personalized medicine and genomics, fuel the need for clinical trials to investigate novel strategies and therapies. In addition, technological innovations in clinical research, such as the adoption of virtual clinical trials and remote monitoring of clinical trial patients, facilitate more cost-effective and efficient clinical trial management, thus supporting the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. Several contract research organizations are penetrating the space of cardiovascular clinical trials. Moreover, these companies are focusing on innovating cardiovascular treatment therapies with experimentation over novel compounds. These players focus on partnerships and collaborations with bio-pharmaceutical companies to enhance their market presence. For instance, in August 2023, Dr. Vince Clinical Research (DVCR); a clinical research organization, announced a strategic alliance with Clario for delivering cardiac assessments in clinical trials.

Furthermore, the globalization of clinical trials is another significant factor supporting the market's growth. For instance, in May 2022, according to the clinical trials arena, the involvement of Western commercial companies in trials run in China has grown gradually from around 100 trials per year in 2010 to around 350 trials in 2021. Hence, this is one of the primary factors supporting the market growth during the forecast period.

The COVID-19 pandemic negatively impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving cardiovascular indications. However, the market recovered by adopting novel trial methods such as virtual and decentralized clinical trials.

Cardiovascular Clinical Trials Market Report Highlights:

• Based on phase, the Phase IV segment accounted for the largest share of 34.3% in 2022. The segment is driven by the growing demand for novel therapeutics and the incorporation of real-world data for enhanced assessment of the post-marketing surveillance process
• Based on the study design, the interventional segment accounted for the largest share of 64.8% in 2022. High segment shares are majorly due to the growing pipeline of cardiovascular therapeutics under controlled interventional clinical trials
• Based on indication, the stroke segment is anticipated to witness the highest CAGR of 6.9% across the analysis timeframe due to the increasing prevalence rate of the condition globally and the surge in the need for innovative stroke treatment therapies
• Asia Pacific is anticipated to witness the highest CAGR of 6.8% during the forecast time frame. High growth is primarily due to the increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Phase
  • 1.1.3. Study Design
  • 1.1.4. Indication
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Cardiovascular Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising burden of cardiovascular diseases globally
    • 3.2.1.2. Globalization of clinical trials
    • 3.2.1.3. Increasing R&D expenditure towards clinical trials
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rigorous approval standards set by regulatory bodies
    • 3.2.2.2. Patient recruitment and retention challenges
• 3.3. Cardiovascular Clinical Trials Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cardiovascular Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Cardiovascular Clinical Trials Market, By Phase: Segment Dashboard
• 4.2. Cardiovascular Clinical Trials Market, By Phase: Movement Analysis
• 4.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Phase, 2018 - 2030
  • 4.3.1. Phase I
    • 4.3.1.1. Phase I Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 4.3.2. Phase II
    • 4.3.2.1. Phase II Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 4.3.3. Phase III
    • 4.3.3.1. Phase III Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
  • 4.3.4. Phase IV
    • 4.3.4.1. Phase IV Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Cardiovascular Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Cardiovascular Clinical Trials Market, By Study Design: Segment Dashboard
• 5.2. Cardiovascular Clinical Trials Market, By Study Design: Movement Analysis
• 5.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Study Design, 2018 - 2030
  • 5.3.1. Interventional
    • 5.3.1.1. Interventional Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.2. Observational
    • 5.3.2.1. Observational Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)
  • 5.3.3. Expanded Access
    • 5.3.3.1. Expanded Access Cardiovascular Clinical Trials Market, 2018 to 2030 (USD Million)

Chapter 6. Cardiovascular Clinical Trials Market: Indication Estimates & Trend Analysis

• 6.1. Cardiovascular Clinical Trials Market, By Indication: Segment Dashboard
• 6.2. Cardiovascular Clinical Trials Market, By Indication: Movement Analysis
• 6.3. Cardiovascular Clinical Trials Market Estimates & Forecasts, By Indication, 2018 - 2030
  • 6.3.1. Acute Coronary Syndrome
    • 6.3.1.1. Acute Coronary Syndrome Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.2. Coronary Artery Disease
    • 6.3.2.1. Coronary Artery Disease Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.3. Ischemic Heart Disease
    • 6.3.3.1. Ischemic Heart Disease Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.4. Pulmonary Arterial Hypertension
    • 6.3.4.1. Pulmonary Arterial Hypertension Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.5. Stroke
    • 6.3.5.1. Stroke Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.6. Cardiac Arrhythmias
    • 6.3.6.1. Cardiac Arrhythmias Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.7. Heart Failure
    • 6.3.7.1. Heart Failure Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)
  • 6.3.8. Others
    • 6.3.8.1. Others Cardiovascular Clinical Trials Market 2018 to 2030 (USD Million)

Chapter 7. Cardiovascular Clinical Trials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2022 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Competitive Scenario
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Competitive Scenario
    • 7.6.1.3. Regulatory Framework
    • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 7.6.2. India
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 7.6.4. South Korea
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 7.7.2. Mexico
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory Framework
    • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
  • 8.1.1. Innovators
  • 8.1.2. Market Leaders
  • 8.1.3. Emerging Players
  • 8.1.4. Company Market Share Analysis, 2022
• 8.2. Company Profiles
  • 8.2.1. IQVIA Inc
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Service Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. ICON plc
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Service Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. SGS SA
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Service Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Eli Lilly and Company
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Service Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. PPD Inc
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Service Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Syneos Health
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Service Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Caidya
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Service Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. Worldwide Clinical Trials
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Service Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. Vial
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Service Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Veeda Clinical Research
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Service Benchmarking
    • 8.2.10.4. Strategic Initiatives
  • 8.2.11. Medpace, Inc.
    • 8.2.11.1. Company Overview
    • 8.2.11.2. Financial Performance
    • 8.2.11.3. Service Benchmarking
    • 8.2.11.4. Strategic Initiatives